For Non-US Residents

About TASMAR

TASMAR® (tolcapone) is an adjunct (additional) oral medicine that is used in combination with other Parkinson’s medicines. It is used in combination with levodopa and carbidopa for patients with severe Parkinson’s disease who are not responding satisfactorily to, or are not appropriate candidates for, other adjunct therapies.

TASMAR is used when other Parkinson’s medicines begin to wear off – that is, becomes less effective over several years of use. When this happens, Parkinson’s symptoms may occur or get worse throughout a day, before it is time for the next dose of medicine. TASMAR helps to counteract this wearing off.

TASMAR Increases ON Time
Most patients experience significant results from taking TASMAR. The average TASMAR patient has an increase in ON time, otherwise known as the time symptoms are controlled. In a 16-hour waking day, it increases ON time an average of 1.7-2.9 hours, and decreases OFF time anywhere from between 1.6 to 3.2 hours.

Learn more about how it works.

What TASMAR Means for You
TASMAR has a unique method of action that allows levodopa and carbidopa to continue to be effective, which can give a patient more ON time and less OFF time without having to increase your levodopa dosage.

TASMAR Liver Monitoring Requirements Revised
Updated TASMAR prescribing information has been approved by the Food and Drug Administration (FDA). Learn more about it, and what it means for you in the Labeling Update section of this Web site.

TASMAR SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT HAS PROVIDED WRITTEN INFORMED CONSENT (SEE PATIENT ACKNOWLEDGEMENT FORM).

WARNING: Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS and DOSAGE AND ADMINISTRATION sections).

TASMAR therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution (see PRECAUTIONS: Rhabdomyolysis).

Laboratory Tests: Although a program of frequent laboratory monitoring for evidence of hepatocellular injury is deemed essential, it is not clear that periodic monitoring of liver enzymes will prevent the occurrence of fulminant liver failure. However, it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery. Accordingly, the following liver monitoring program is recommended.

Please see accompanying complete prescribing information including BOXED warning.

© Valeant Pharmaceuticals International 2006 Legal and Privacy Statement
TASMAR® is a registered trademark of Valeant Pharmaceuticals International